Test categories
Select one of the categories below to learn more.
Specialized microbiological cultures and laboratory analyses for the detection of infections affecting the gynecological and urogenital system, including advanced culture techniques and antibiograms.
| DESCRIPTION | METHODOLOGY |
| Comprehensive Vaginal Culture (Aerobic–Anaerobic–Mycoplasma–Ureaplasma–Chlamydia) Free Antibiogram Included |
Culture on selective media |
| Comprehensive Urethral Culture (Aerobic–Anaerobic–Mycoplasma–Ureaplasma–Chlamydia) | Culture on selective media |
| Rectal Swab Culture for detection of Group B β-hemolytic Streptococcus | Culture on selective media |
| Nipple Discharge Culture | Culture on selective media |
| Intrauterine Device (IUD) Culture | Culture on selective media |
| Antibiogram | Kirby–Bauer |
| Antifungigram | Kirby–Bauer |
Cytological screening with Thin Prep and conventional Pap test for the prevention and early detection of cervical abnormalities and related conditions.
| DESCRIPTION | METHODOLOGY |
| ThinPrep (Liquid-Based Pap Test) | Liquid-Based Cytology – Papanicolaou Staining |
| Pap Test (Conventional Smear) | Conventional Cytology – Papanicolaou Staining |
| Breast Cytology | Liquid-Based Cytology – Papanicolaou Staining |
Advanced PCR and Real-Time PCR molecular testing for the detection of sexually transmitted pathogens, including HPV, Chlamydia, Mycoplasma, Ureaplasma, HSV and more.
| DESCRIPTION | METHODOLOGY |
| Chlamydia trachomatis | PCR |
| Mycoplasma hominis | PCR |
| Ureaplasma urealyticum | PCR |
| Chlamydia trachomatis – Ureaplasma urealyticum – Mycoplasma hominis | PCR |
| STIs – Detection of Sexually Transmitted Pathogens (Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Mycoplasma hominis (Mh), Herpes simplex virus type 1 (HSV1), Ureaplasma urealyticum (UU), Herpes simplex virus type 2 (HSV2), Ureaplasma parvum (UP), Mycoplasma genitalium (Mg), Candida albicans (CA), Gardnerella vaginalis (GV), Trichomonas vaginalis (TV), Group B streptococci (GBS), Haemophilus ducreyi (HD), and Treponema pallidum (TP)) | Multiplex Real-Time PCR |
| Neisseria gonorrhoeae (gonococcus) | Real-Time PCR |
| Chlamydiaceae (Chlamydia family) | Real-Time PCR |
| Chlamydia trachomatis | Real-Time PCR |
| Mycoplasma genitalium | Real-Time PCR |
| Ureaplasma parvum | Real-Time PCR |
| Ureaplasma urealyticum | Real-Time PCR |
| Treponema pallidum (syphilis) | Real-Time PCR |
| Candida albicans | Real-Time PCR |
| HHV-1/2 (HSV) – Herpes Simplex Virus | Real-Time PCR |
STI Screening Package
| DESCRIPTION | METHODOLOGY |
| STIs – Detection of Sexually Transmitted Pathogens | Multiplex Real-Time PCR |
| HIV-I & II Antibodies | CLIA |
| Hepatitis B Virus (HBsAg) Surface Antigen | CLIA |
| Hepatitis C Virus (HCV) Antibodies | CLIA |
| VDRL Antibodies | Immunological Assay |
Comprehensive virology testing for clinically significant viruses such as HPV, CMV, EBV, HSV, HIV and hepatitis viruses using reliable molecular and immunological methodologies.
| DESCRIPTION | METHODOLOGY |
| Rubella Virus | Real-Time PCR (CE-IVD) |
| Human Cytomegalovirus HHV-5 (CMV) | Real-Time PCR (CE-IVD) |
| Epstein–Barr Virus HHV-4 (EBV) | Real-Time PCR (CE-IVD) |
| Herpes Simplex Virus HHV-1/2 (HSV) | Real-Time PCR (CE-IVD) |
| Varicella-Zoster Virus HHV-3 (VZV) | Real-Time PCR (CE-IVD) |
| Hepatitis B Virus (HBV) | Real-Time PCR (CE-IVD) |
| Hepatitis C Virus (HCV) | Real-Time PCR (CE-IVD) |
| Hepatitis C Virus (HCV) – Genotype | Real-Time PCR (CE-IVD) |
| HIV-I | Real-Time PCR (CE-IVD) |
| HIV-II | Real-Time PCR |
| HIV-I & II Antibodies | CLIA |
| Hepatitis D Virus (HDV) | Real-Time PCR (CE-IVD) |
| T4/T8 Lymphocyte Subpopulations | Flow Cytometry |
Genetic investigations for chromosomal abnormalities through karyotyping and molecular karyotyping (arrCGH) in individuals, couples and miscarriage tissue samples.
| DESCRIPTION | METHODOLOGY |
| Peripheral Blood Karyotype (Individual) | G-Banding |
| Peripheral Blood Karyotype (Couple) | G-Banding |
| Molecular Karyotype (Individual) | arrCGH |
| Karyotype Analysis in Products of Conception Tissue | G-Banding |
Specialized laboratory and genetic investigations related to female infertility and reproductive health assessment.
| DESCRIPTION | METHODOLOGY |
| Peripheral Blood Karyotype (Individual) | G-Banding |
| Peripheral Blood Karyotype (Couple) | G-Banding |
| Inhibin B | ELISA |
| Anti-Müllerian Hormone (AMH) | ECLIA |
| NK Cells | Flow Cytometry |
| DESCRIPTION | METHODOLOGY |
| Peripheral Blood Karyotype (Individual)* | G-Banding |
| Inhibin B | ELISA |
| Anti-Müllerian Hormone (AMH) | ECLIA |
| NK Cells | Flow Cytometry |
| Fragile X | PCR-HRM |
| CVD-13* | PCR-Hybridization (CE-IVD) |
Comprehensive male fertility evaluation including semen analysis, microbiological testing, DNA fragmentation analysis and advanced molecular investigations.
| DESCRIPTION | METHODOLOGY |
| Peripheral Blood Karyotype (Individual) | G-Banding |
| Peripheral Blood Karyotype (Couple) | G-Banding |
| Semen Analysis | WHO 6th Edition (2021) analysis using Phase Contrast microscopy and morphological assessment by cytological staining |
| Semen Culture | Culture using selective growth media |
| Sperm DNA Fragmentation | Flow cytometry – DCFDA/DHE assay kit, Abcam™ |
| Y Chromosome Microdeletion Analysis | Multiplex PCR |
| Fragile X | PCR-HRM |
| Oxidative Stress Assessment | Flow cytometry – DCFDA/DHE assay kit, Abcam™ |
| Sperm Apoptosis | Flow Cytometry |
| Seminal Fructose | Enzymatic photometric assay |
| Seminal Citric Acid | Enzymatic spectrophotometric method (UV, 37°C) |
| α-Glucosidase in Seminal Fluid | Spectrophotometry |
| Seminal Zinc | 5-Br-PAPS photometric assay |
| Infertility Gene Panel (WES-NGS) | NGS |
Male Infertility Package 1
| DESCRIPTION | METHODOLOGY |
| Semen Analysis | WHO 6th Edition |
| Semen Culture | Using selective culture media |
Male Infertility Package 2
| DESCRIPTION | METHODOLOGY |
| Seminal Fructose | Enzymatic photometric assay |
| Seminal Citric Acid | UV Spectrophotometry |
| α-Glucosidase in Seminal Fluid | Spectrophotometry |
| Seminal Zinc | 5-Br-PAPS photometric assay |
Male Infertility Package 3
| DESCRIPTION | METHODOLOGY |
| Molecular Analysis for Cystic Fibrosis by NGS (mutations & deletions/duplications) | NGS (CE-IVD) |
| Peripheral Blood Karyotype | G-Banding |
| Y Chromosome Microdeletion Analysis | Multiplex PCR |
Male Infertility Package 4
| DESCRIPTION | METHODOLOGY |
| Semen Analysis | WHO 6th Edition |
| Semen Culture | Using selective culture media |
| Sperm DNA Fragmentation | Flow cytometry–Tunel assay kit, Apo direct, BD Pharmingen™ |
| Oxidative Stress Assessment | Flow cytometry–DCFDA/DHE assay kit, Abcam™ |
Molecular and immunological testing for inherited and acquired thrombophilia associated with pregnancy and reproductive health.
| DESCRIPTION | METHODOLOGY |
| Factor V Mutation (V-Leiden G1691A) | Real-Time PCR (CE-IVD) |
| Factor V Mutation (R2: H1299A) | PCR-Hybridization (CE-IVD) |
| Prothrombin Mutation (Factor II: G20210A) | Real-Time PCR (CE-IVD) |
| MTHFR Mutation (C677T) | Real-Time PCR (CE-IVD) |
| MTHFR Mutation (A1298C) | Real-Time PCR (CE-IVD) |
| Plasminogen Activator Inhibitor Mutation (PAI-1: -675, 4G/5G) | Real-Time PCR (CE-IVD) |
| Plasminogen Activator Inhibitor Mutation (PAI-1: -844, G>A) | PCR-Hybridization (CE-IVD) |
| GPIa Glycoprotein Polymorphism | Real-Time PCR (CE-IVD) |
| Apolipoprotein E Polymorphisms (APO E2/E3/E4) | PCR-Hybridization (CE-IVD) |
| Lupus Anticoagulant (LAC) | Coagulation assay based on dilute Russell’s viper venom time (dRVVT) |
| Antithrombin III | Chromogenic assay |
| ACA (Centromere Antibodies) | CMIA |
| Protein C Activity | Coagulation assay |
| Free Protein S Antigen | Latex Immunoassay (LIA) |
| β2 Glycoprotein I Ab IgG | CMIA |
| β2 Glycoprotein I Ab IgM | CMIA |
| β2 Glycoprotein I Ab IgA | CLIA |
| APC-R (Activated Protein C Resistance) | Coagulation assay |
| Antinuclear Antibodies (ANA) | Indirect Immunofluorescence Assay (IFA) |
| dsDNA Antibodies | CMIA |
| Serum Homocysteine (HCY) | CLIA |
| Anticardiolipin Antibodies IgG | CMIA |
| Anticardiolipin Antibodies IgM | CMIA |
| Anticardiolipin Antibodies IgA | CLIA |
Integrated thrombophilia testing packages combining molecular, biochemical and immunological analyses tailored to each patient’s needs.
| Basic Molecular Panel – 3 Markers | ||
| DESCRIPTION | METHODOLOGY | |
| Factor V (LEIDEN G1691A) | PCR-Hybridization (CE-IVD) | |
| Factor II (G20210A) | PCR-Hybridization (CE-IVD) | |
| MTHFR (C677T) | PCR-Hybridization (CE-IVD) | |
| Molecular Panel – 4 Markers | ||
| DESCRIPTION | METHODOLOGY | |
| Factor V (LEIDEN G1691A) | PCR-Hybridization (CE-IVD) | |
| Factor II (G20210A) | PCR-Hybridization (CE-IVD) | |
| MTHFR (C677T) | PCR-Hybridization (CE-IVD) | |
| GPIa | PCR-Hybridization (CE-IVD) | |
| Molecular Panel – 8 Markers (CVD-T) | ||
| DESCRIPTION | METHODOLOGY | |
| Factor II (G20210A) | PCR-Hybridization (CE-IVD) | |
| Factor V (G1691A) | PCR-Hybridization (CE-IVD) | |
| Factor V (R2 H1299A) | PCR-Hybridization (CE-IVD) | |
| MTHFR (A1298C) | PCR-Hybridization (CE-IVD) | |
| MTHFR (C677T) | PCR-Hybridization (CE-IVD) | |
| Factor XIII (V34L) | PCR-Hybridization (CE-IVD) | |
| PAI-1 | PCR-Hybridization (CE-IVD) | |
| EPCR (A1,A3) | PCR-Hybridization (CE-IVD) | |
| Molecular Panel – 8 Markers (CVD-A) | ||
| DESCRIPTION | METHODOLOGY | |
| ACE | PCR-Hybridization (CE-IVD) | |
| ApoB | PCR-Hybridization (CE-IVD) | |
| ApoE | PCR-Hybridization (CE-IVD) | |
| GPIIIa | PCR-Hybridization (CE-IVD) | |
| Fibrinogen-β | PCR-Hybridization (CE-IVD) | |
| eNOS (G894S) | PCR-Hybridization (CE-IVD) | |
| eNOS (-786 T>C) | PCR-Hybridization (CE-IVD) | |
| LTA | PCR-Hybridization (CE-IVD) | |
| Basic Thrombophilia Screening | Extended Thrombophilia Screening | Comprehensive Thrombophilia Screening |
| APTT | APTT | APTT |
| PT | PT | PT |
| Fibrinogen | Fibrinogen | Fibrinogen |
| Homocysteine | Homocysteine | Homocysteine |
| Antithrombin III | Antithrombin III | Antithrombin III |
| Anticardiolipin IgG | Anticardiolipin IgG | Anticardiolipin IgG |
| Anticardiolipin IgM | Anticardiolipin IgM | Anticardiolipin IgM |
| Protein C | Protein C | Protein C |
| Protein S | Protein S | Protein S |
| Antinuclear Antibodies (ANA) | Antinuclear Antibodies (ANA) | Antinuclear Antibodies (ANA) |
| MTHFR C677T Molecular Analysis | MTHFR C677T Molecular Analysis | MTHFR C677T Molecular Analysis |
| 13-Marker Thrombophilia Molecular Panel | 13-Marker Thrombophilia Molecular Panel | 13-Marker Thrombophilia Molecular Panel |
| Lupus Anticoagulant (LAC) | Lupus Anticoagulant (LAC) | |
| APC Resistance (APC-R) | ||
| β2-Glycoprotein I Antibodies IgG | ||
| β2-Glycoprotein I Antibodies IgM | ||
| 13-Marker Molecular Panel | ||
| DESCRIPTION | METHODOLOGY | |
| Factor II (G20210A) | PCR-Hybridization (CE-IVD) | |
| Factor V (R2 H1299A) | PCR-Hybridization (CE-IVD) | |
| MTHFR (C677T) | PCR-Hybridization (CE-IVD) | |
| MTHFR (A1298C) | PCR-Hybridization (CE-IVD) | |
| Factor V (G1691A) | PCR-Hybridization (CE-IVD) | |
| Fibrinogen-β (455G>A) | PCR-Hybridization (CE-IVD) | |
| Factor XIII (V34L) | PCR-Hybridization (CE-IVD) | |
| PAI-1 (PAI-1 PCR) | PCR-Hybridization (CE-IVD) | |
| Platelet Glycoproteins (HPA-1 L33P) | PCR-Hybridization (CE-IVD) | |
| Apolipoprotein B (R3500Q) | PCR-Hybridization (CE-IVD) | |
| Apolipoprotein E (E2/E3/E4) | PCR-Hybridization (CE-IVD) | |
| Angiotensin-Converting Enzyme (ACE I/D) | PCR-Hybridization (CE-IVD) | |
| Glycoprotein IIIa (C807T) | PCR-Hybridization (CE-IVD) |
Genetic carrier screening for common and rare inherited disorders, including thalassemia, cystic fibrosis, SMA and other genetic syndromes.
| Hemoglobinopathies | |
| DESCRIPTION | METHODOLOGY |
| Screening for Thalassemia (α + β) | PCR – Reverse Hybridization (CE-IVD) |
| Molecular Hemoglobinopathy Analysis (α-globin chain) – α-Thalassemia Screening | PCR – Reverse Hybridization (CE-IVD) |
| Molecular Hemoglobinopathy Analysis (β-globin chain) – β-Thalassemia Screening | PCR – Reverse Hybridization (CE-IVD) |
| Molecular Testing for δβ-Thalassemia | PCR |
| Mediterranean Anemia Package | |
| DESCRIPTION | METHODOLOGY |
| Molecular Hemoglobinopathy Analysis (α-globin chain) – α-Thalassemia Screening | PCR – Reverse Hybridization (CE-IVD) |
| Molecular Hemoglobinopathy Analysis (β-globin chain) – β-Thalassemia Screening | PCR – Reverse Hybridization (CE-IVD) |
| Molecular Testing for δβ-Thalassemia | PCR |
| Complete Blood Count (CBC) | Automated 5-Part Hematology Analyzer |
| Iron (Fe) | Enzymatic Chromatography |
| Ferritin | CLIA |
| Hemoglobin Electrophoresis | Electrophoresis |
| Cystic Fibrosis (CFTR) | |
| DESCRIPTION | METHODOLOGY |
| Cystic Fibrosis ΔF508 Molecular Analysis | Real-Time PCR |
| Cystic Fibrosis Molecular Analysis (76.5–85% Mutation Coverage) | PCR – Hybridization (CE-IVD) |
| Cystic Fibrosis Molecular Analysis by NGS (Mutations & Deletions/Duplications) | NGS (CE-IVD) |
| CFTR Deletion/Duplication Analysis | MLPA |
| Rare Genetic Disorders | |
| DESCRIPTION | METHODOLOGY |
| SMA – Molecular Analysis for Spinal Muscular Atrophy | MLPA |
| Duchenne/Becker Muscular Dystrophy | MLPA |
| 35delG Screening for Autosomal Recessive Non-Syndromic Hearing Loss | ARMS-PCR |
| CYP21A Analysis for Congenital Adrenal Hyperplasia | PCR – Hybridization (CE-IVD) |
| Familial Mediterranean Fever (MEFV – 12 Common Mutations) | PCR – Hybridization (CE-IVD) |
| PRE-DNA TEST (Preconception screening of >9,300 inherited disorders by WES) | NGS |
Combined prenatal genetic testing packages designed for comprehensive reproductive and pregnancy evaluation.
| Package 1 | |
| DESCRIPTION | METHODOLOGY |
| Molecular Analysis for Cystic Fibrosis (mutations & deletions/duplications) | NGS (CE-IVD) |
| SMA – Molecular Analysis for Spinal Muscular Atrophy | MLPA |
| 35delG Screening for Autosomal Recessive Hearing Loss | ARMS-PCR |
| Package 2 | |
| DESCRIPTION | METHODOLOGY |
| Peripheral Blood Karyotype (Individual) | G-Banding |
| SMA – Molecular Analysis for Spinal Muscular Atrophy | MLPA |
| Molecular Analysis for Cystic Fibrosis (mutations & deletions/duplications) | NGS (CE-IVD) |
| 35delG Screening for Autosomal Recessive Hearing Loss | ARMS-PCR |
| CVD-3 | PCR-Hybridization (CE-IVD) |
| Package 3 | |
| DESCRIPTION | METHODOLOGY |
| Peripheral Blood Karyotype (Individual) | G-Banding |
| SMA – Molecular Analysis for Spinal Muscular Atrophy | MLPA |
| Molecular Analysis for Cystic Fibrosis (mutations & deletions/duplications) | NGS (CE-IVD) |
| 35delG Screening for Autosomal Recessive Hearing Loss | ARMS-PCR |
| CVD-13 | PCR-Hybridization (CE-IVD) |
| Package 4 | |
| DESCRIPTION | METHODOLOGY |
| PRE-DNA – Carrier Screening for >300 Autosomal Recessive Disorders | NGS |
| Fragile X | PCR-HRM |
| SMA – Molecular Analysis for Spinal Muscular Atrophy | MLPA |
| Thalassemia Screening (α + β) | PCR – Reverse Hybridization (CE-IVD) |
| Molecular Analysis for δβ-Thalassemia | PCR |
Non-Invasive Prenatal Testing (NIPT) is an advanced and reliable prenatal screening method performed through a simple maternal blood draw from the 10th week of pregnancy.
At Science Labs Genotypos, we provide advanced NIPT solutions, including VERACITY™ and VERAgene™, offering high-accuracy and scientifically validated screening for chromosomal abnormalities and selected genetic conditions.
Discover more about:
available NIPT tests, package comparisons, the testing process, recommended pregnancy weeks, the capabilities and limitations of screening, as well as useful educational material for both expectant parents and healthcare professionals.
Visit our dedicated NIPT website:
Explore prenatal genetic screening at NIPT.gr
Biochemical pregnancy screening tests such as PAPP-A and A-test for first and second trimester prenatal assessment.
| DESCRIPTION | METHODOLOGY |
| PAPP-A test | ECLIA |
| A-test | CLIA (including AFP, hCG and Free E3 measurements) |
Advanced prenatal genetic investigations using amniotic fluid and chorionic villus sampling with QF-PCR, karyotyping and molecular karyotyping techniques.
| DESCRIPTION | METHODOLOGY |
| Molecular Karyotype | arrCGH |
| Karyotype Analysis in Amniotic Fluid / Chorionic Villi | G-banding |
| QF-PCR (Fetal Aneuploidies: 13, 18, 21, X, Y, F508del) | PCR |
| Microdeletion Syndrome Screening (e.g. DiGeorge, Williams) | arrCGH |
| Subtelomeric Region Analysis | G-banding |
| WES – Investigation of Ultrasound Findings (amniotic fluid / chorionic villi) | PCR |
| Package 1 | |
| DESCRIPTION | METHODOLOGY |
| Molecular Karyotype | arrCGH |
| QF-PCR | PCR |
| Karyotype Analysis in Amniotic Fluid / Chorionic Villi | G-banding |
| Package 2 | |
| DESCRIPTION | METHODOLOGY |
| Molecular Karyotype | arrCGH |
| QF-PCR | PCR |
| Package 3 | |
| DESCRIPTION | METHODOLOGY |
| Karyotype Analysis in Amniotic Fluid / Chorionic Villi | G-banding |
| QF-PCR | PCR |
Specialized genomic analyses using WES, arrCGH, Sanger Sequencing and HLA typing for the investigation of inherited genetic disorders.
| Genomic Analyses | |
| DESCRIPTION | METHODOLOGY |
| Molecular Karyotype (High Resolution) | arrCGH |
| Whole Exome Sequencing (WES) – 19,000 genes | NGS |
| Clinical genetic interpretation of genomic analysis results (up to 10 genes) | SOPHiA GENETICS DDM |
| Clinical genetic interpretation of genomic analysis results (11–50 genes) | SOPHiA GENETICS DDM |
| Clinical genetic interpretation of genomic analysis results (51–500 genes) | SOPHiA GENETICS DDM |
| Clinical genetic interpretation of genomic analysis results (>500 genes) | SOPHiA GENETICS DDM |
| Sanger Sequencing | Sanger Sequencing |
| Gene sequencing panel (12 variants: V33M, V59M, H63D, H63H, S65C, Q127H, P160delC, E168Q, E168K, W169X, C282Y, Q283P), TFR2 gene (4 variants: E60X, M172K, Y250X, AIV4G594-597del), and FPN1 gene (2 variants: N144H, V162del) | PCR–Hybridization (CE-IVD) |
| HLA Typing | |
| DESCRIPTION | METHODOLOGY |
| HLA-B27 Histocompatibility Antigen | PCR |
| HLA-A Molecular Typing | PCR–Hybridization (CE-IVD) |
| HLA-B Typing | PCR–Hybridization (CE-IVD) |
| HLA-C Typing | PCR–Hybridization (CE-IVD) |
| HLA-DRB1 Typing | PCR–Hybridization (CE-IVD) |
| HLA-DQA1 Typing | PCR–Hybridization (CE-IVD) |
| HLA-DQ2 + DQ8 | PCR–Hybridization (CE-IVD) |
| HLA Class I Molecular Typing (A, B, C) | PCR–Hybridization (CE-IVD) |
| NK Cells | Flow Cytometry |
Targeted genomic testing for hereditary cancer syndromes, BRCA1/2 analysis, infertility genetics and preventive reproductive screening.
| DESCRIPTION | METHODOLOGY |
| BRCA 1/2 (Germline, NGS) | NGS |
| BRCA 1/2 – MLPA (Deletions/Duplications) | MLPA |
| Hereditary Gynecological Cancer Panel (109 genes) | NGS |
| PRE-DNA TEST (preconception screening for >300 inherited disorders through WES), including testing for Fragile X, SMA and α-thalassemia | NGS |
| Infertility Gene Panel – WES | NGS |
Science Labs Genotypos provides comprehensive diagnostic services in women’s health, reproductive medicine and prenatal genetics. Through advanced laboratory methodologies and specialized scientific expertise, we support women, couples and healthcare professionals with reliable and evidence-based diagnostic solutions.
Science Labs Genotypos provides a comprehensive range of clinical and routine laboratory examinations supporting prevention, diagnosis and everyday health monitoring through reliable and modern laboratory methods.
Our laboratory services include hematological, biochemical, hormonal and urine analyses, designed to support both preventive screening and physician-directed clinical investigation.
In this section, you can explore available laboratory examinations, routine check-up packages and selected diagnostic panels with detailed information regarding the included tests and available options.
Explore our laboratory examinations
Testing for allergies related to airborne allergens such as pollens, dust mites, molds, animal epithelia and other environmental allergens.
Investigation of food allergies and intolerances through specialized panels and specific IgE antibody analysis.
Assessment of suspected allergic reactions to medications through specialized laboratory testing, supporting the investigation of immediate and delayed drug hypersensitivity reactions.
Evaluation of allergic reactions associated with environmental and seasonal allergens.
Combined testing panels for the investigation of multiple allergens using advanced laboratory methodologies.
Specialized allergy investigations tailored to infants and pediatric patients.
The Science Labs Genotypos provides modern and reliable allergy testing services for the investigation of respiratory, food and environmental allergies through specialized immunological analyses and specific IgE panels.
Our testing services are designed to support clinical diagnosis and personalized patient evaluation for both children and adults.
The laboratory is equipped with the Phadia™ 250 system, an internationally recognized allergy and immunology testing platform offering high reliability and accuracy in the detection of specific IgE antibodies.
The Science Labs Genotypos diagnostic laboratory collaborates with EOPYY and selected insurance providers for the performance of diagnostic laboratory examinations.
In order to perform your examinations through your insurance provider, please make sure to have:
– A valid medical referral from your physician
– Your identification document
– Your insurance information or health coverage details
Please ensure that:
– the referral includes the physician’s signature and stamp where required,
– the referral remains within its valid execution period.
Collaborating Insurance Providers
EOPYY
IKA
OAEE / TEVE
Public Sector Insurance Funds
TSMEDE
OGA
NAT / House of Sailor
TYDKY
TSAY
ETAP-MME
European Citizen Coverage
Military Insurance Funds
Hellenic Army
Hellenic Navy
Hellenic Air Fοrce
Coast Guard
– Unified Journalists’ Auxiliary Insurance and Healthcare Organization (EDOEAP)
The Science Labs Genotypos diagnostic laboratory also participates as a collaborating diagnostic center in preventive healthcare and population screening programs.
More specifically, the laboratory participates in:
– The national “PROLAMVANO” program for cervical cancer prevention
– The national “PROLAMVANO” program for cardiovascular disease prevention